Author

J. Gayle

Observed names: J Gayle, J.A. Gayle

Institution: Baylor College of Medicine

Observed institutions: Baylor College of Medicine, Eisai (United States)

OpenAlex ID: A5113890449

Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals

2018 · B. Buckley, J. Dreyfus, et al. · Haemophilia · 9

PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study

2021 · E. Mozaffari, A. Chandak, et al. · Value in Health · 3

The Safety and Tolerability of Veliparib (V) plus Capecitabine (C) and Radiation (RT) in Subjects with Locally Advanced Rectal Cancer (LARC): Results of a Phase 1b Study

2014 · B. Czito, M. Mulcahy, et al. · International Journal of Radiation Oncology*Biology*Physics · 3

Pcn171 Cost and Healthcare Resource Utilization (hru) Resulting From Immune-related Adverse Events (iraes) Among Patients Receiving Immune Checkpoint Inhibitors (icis)

2019 · Y. Zheng, R. Kim, et al. · Value in Health · 2

Real world outcomes of immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitors (ICIs) in hospital settings

2019 · S. George, Y. Zheng, et al. · Annals of Oncology · 2

Pcn48 Impact on Hospital Outpatient Visit Costs by Initiating Palonosetron Versus Other 5-hydroxytryptamine3 Receptor Antagonists for Prevention of Chemotherapy Induced Nausea and Vomiting (cinv) Among Patients With Cancer

2011 · C. Craver, J. Gayle, et al. · Value in Health · 2

354 Administration of Potassium Binders in the Emergency Department Reduces Return Visits

2023 · Z. Rafique, J. Neuenschwander, et al. · Annals of Emergency Medicine

HSD13 Emergency Department Hyperkalemia Outcomes Are Improved with Newer Potassium Binders

2023 · N. Rosenthal, J. Gayle, et al. · Value in Health

Pcn317 Real-world Study of Metastatic Merkel Cell Carcinoma Patients Receiving Checkpoint Inhibitors (cpis) Vs. Chemotherapy Treatments

2019 · Y. Zheng, R. Kim, et al. · Value in Health

PIN14 Resource Utilization and Costs of Treating Complicated Skin and Skin Structure Infections With Daptomycin or Telavancin

2012 · R. Luo, P. Chaudhari, et al. · Value in Health

Pcn1 Chemotherapy Induced Nausea and Vomiting Event Rate Among Patients With Cancer Treated With Highly or Moderately Emetogenic Chemotherapy and Initiated on Palonosetron Versus Other 5-ht3-receptor Antagonist Anti-emetic Prophylaxis in a Hospital Outpatient Setting

2011 · C. Craver, J. Gayle, et al. · Value in Health

Cn4 Palonosetron Versus Other 5-hydroxytryptamine3 Receptor Antagonists for Prevention of Chemotherapy Induced Nausea and Vomiting Among Medicare Patients With Cancer

2011 · C. Craver, J. Gayle, et al. · Value in Health

Palonosetron versus other 5-HT3–receptor antagonists for chemotherapy-induced nausea and vomiting prevention in patients with noncolon gastrointestinal cancers.

2011 · S. Balu, C. Craver, et al. · Journal of Clinical Oncology

Pcn2 Palonosetron Versus Other 5-ht3-receptor Antagonists in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Cancer Treated in a Hospital Outpatient Setting

2010 · C Craver, J Gayle, et al. · Value in Health

Pcn3 Chemotherapy-induced Nausea and Vomiting Events by Chemotherapy Emetogenicity in Patients With Cancer Treated in a Hospital Outpatient Setting

2010 · C Craver, J Gayle, et al. · Value in Health

Works count: 15

Citation count: 21

H-index: 3

I10-index: